Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
Go back to Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.02 -0.01 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.03 | 52 Week High | $3.50 | |||
| Open | $1.05 | 52 Week Low | $0.86 | |||
| Day High | $1.05 | P/E | N/A | |||
| Day Low | $1.01 | EPS | $-7.61 | |||
| Volume | 40,483 | |||||
